Company profile for STCube

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

STCube is an innovation-driven biotech company focused on developing precision immunotherapies for treatment-resistant and recurrent cancers. Backed by cutting-edge research, STCube has pioneered Nelmastobart, the world?s first antibody targeting BTN1A1. With a mission rooted in persistent innovation, the company aims to deliver faster, safer, and more effective cancer treatments, offering new hope to patients worldwide throug...
STCube is an innovation-driven biotech company focused on developing precision immunotherapies for treatment-resistant and recurrent cancers. Backed by cutting-edge research, STCube has pioneered Nelmastobart, the world?s first antibody targeting BTN1A1. With a mission rooted in persistent innovation, the company aims to deliver faster, safer, and more effective cancer treatments, offering new hope to patients worldwide through breakthrough science and personalized medicine.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
South Korea
Address
Address
2201, Trade Center Trade Tower, 511 Yeongdong-daero, Gangnam-gu, Seoul
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

AMWC Asia-TDAC

AMWC Asia-TDAC

Not Confirmed

envelop Contact Supplier

AMWC Asia-TDAC

Post an Enquiry

Meeting

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty